Related Experiment Video

Updated: May 18, 2026

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential
07:41

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential

Published on: January 18, 2019

Potent selective inhibition of STAT 3 versus STAT 1 by cardiac hormones

Meghan L Lane1, Chelsea D Frost, Jennifer P Nguyen

  • 1Department of Medicine, USF Cardiac Hormone Center, James A. Haley VA Medical Center and University of South Florida, 13000 Bruce B. Downs Blvd, Tampa, FL 33612, USA. megja.vu@gmail.com

Molecular and Cellular Biochemistry
|September 12, 2012
PubMed

Insights

Four cardiovascular hormones significantly inhibit STAT 3, a key factor in human cancers, but not STAT 1. This suggests a specific anticancer mechanism for these hormones in lung and pancreatic cancer cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Signal transducers and activators of transcription (STATs) are critical regulators of gene expression implicated in human cancers.
  • Extracellular signal-regulated kinases (ERK 1/2) activate STAT 3, a pathway often dysregulated in malignancy.
  • Cardiovascular hormones, including vessel dilator, long-acting natriuretic peptide (LANP), kaliuretic peptide, and atrial natriuretic peptide (ANP), have demonstrated anticancer effects in preclinical models.

Purpose of the Study:

  • To investigate the inhibitory effects of four cardiovascular hormones on STAT 1 and STAT 3 signaling pathways.
  • To determine if these hormones exhibit specificity in their inhibition of STAT 1 versus STAT 3.
  • To explore the potential anticancer mechanisms of these hormones in human cancer cells.

Main Methods:

  • Human small-cell lung cancer and human pancreatic adenocarcinoma cell lines were utilized.
  • The effects of vessel dilator, LANP, kaliuretic peptide, and ANP on STAT 1 and STAT 3 levels were assessed.
  • Quantitative analysis included Western blotting to measure protein expression levels.

Main Results:

  • All four cardiac hormones significantly decreased STAT 3 levels in both small-cell lung cancer and pancreatic adenocarcinoma cells at 1 μM concentrations.
  • Specific maximal decreases in STAT 3 were observed: 88% (vessel dilator), 54% (LANP), 55% (kaliuretic peptide), and 65% (ANP) in lung cancer cells, and 66%, 57%, 70%, and 77% in pancreatic cancer cells, respectively.
  • These hormones did not significantly decrease STAT 1 levels in either cell type, indicating specificity.

Conclusions:

  • The four investigated cardiac hormones are potent inhibitors of STAT 3 in human small-cell lung cancer and pancreatic adenocarcinoma cells.
  • The observed inhibition of STAT 3, without affecting STAT 1, suggests a specific molecular mechanism for their anticancer activity.
  • These findings highlight the potential of cardiovascular hormones as targeted therapies for STAT 3-driven malignancies.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...